GIP Academy: The Complete Evidence-Based Guide to GIP, GIPR & GIP-Based Peptide Therapies

Updated October 1, 2026

Glucose-dependent insulinotropic polypeptide (GIP) was once overshadowed by GLP-1, but it has become one of the most important targets in modern metabolic medicine. The development of tirzepatide, a dual GIP receptor/GLP-1 receptor agonist, and the rapid development of retatrutide, a GIP/GLP-1/glucagon triple agonist, have moved GIP from a relatively obscure incretin hormone into a central part of obesity and diabetes drug research.

At the same time, GIP biology is more complicated than the popular description of GIP as simply "the second hormone in tirzepatide." Researchers are studying both GIP receptor agonism and GIP receptor antagonism, two apparently opposite strategies that have both shown potential for improving metabolic outcomes. The mechanisms behind this paradox remain an active area of research.

This GIP Academy explains what GIP is, how GIPR signaling works, how GIP differs from GLP-1, what is known about tirzepatide and other GIP-targeting therapies, what the latest retatrutide evidence shows, and where the major uncertainties remain.

Key point: GIP, GIPR and GIP-based medicines are not interchangeable terms. GIP is a naturally occurring hormone; GIPR is its receptor; and drugs such as tirzepatide and retatrutide are engineered molecules that manipulate GIPR together with one or more other metabolic receptors.

GIP Academy Contents

What Is GIP?

GIP stands for glucose-dependent insulinotropic polypeptide. It is an incretin hormone produced primarily by specialized enteroendocrine K cells in the upper small intestine in response to food intake.

GIP was originally identified because of its effects on gastric acid secretion and was initially called gastric inhibitory polypeptide. Its more important physiological role became clearer as researchers established that it enhances glucose-dependent insulin secretion. It is now recognized as a pleiotropic metabolic hormone with effects that extend beyond the pancreas.

After nutrients enter the digestive tract, GIP is released and interacts with the GIP receptor (GIPR). GIP signaling participates in the regulation of insulin secretion, glucose handling and nutrient metabolism. Modern research is also examining its effects in adipose tissue, the central nervous system and other organs.

A 2025 review describes GIP as the first incretin discovered and emphasizes its broader metabolic functions beyond the endocrine pancreas. [PubMed: GIP review]

GIP is an incretin hormone

An incretin is a hormone released after eating that helps coordinate nutrient metabolism, including insulin secretion. GIP and GLP-1 are the principal incretin hormones targeted by modern incretin-based medicines.

Importantly, GIP is not simply a naturally occurring "weight-loss peptide." Its physiological functions are context-dependent, and clinical outcomes from manipulating GIP signaling depend on the drug, receptor target, dose, combination partner and patient population.

How Does GIP Work?

GIP signaling can be understood as part of the body's nutrient-sensing network. Food intake triggers intestinal hormone secretion, which then helps coordinate the handling of glucose, fat and other nutrients.

Process Role of GIP Evidence context
Insulin secretion GIP stimulates insulin secretion in a glucose-dependent manner. Well established physiology
Glucose regulation GIP contributes to post-meal glucose control through incretin signaling. Human physiology
Adipose tissue GIP signaling can influence lipid handling and adipocyte biology. Complex; context dependent
Brain GIPR is expressed in regions involved in metabolic and appetite regulation. Active translational research
Body weight Pharmacological manipulation of GIPR can influence body weight, particularly in combination with other receptor targets. Strong evidence for some drugs; mechanisms still under study

GIP biology therefore cannot be reduced to a single effect such as "increases insulin" or "causes fat storage." Its actions depend on the physiological and pharmacological context.

Recent reviews emphasize that GIP is a multifaceted hormone and that its effects outside the pancreas are important to understanding why GIPR-targeting medicines behave differently from simple GIP replacement. [PubMed: Physiology and clinical applications of GIP]

What Is the GIP Receptor (GIPR)?

GIPR means glucose-dependent insulinotropic polypeptide receptor. It is the receptor through which GIP exerts many of its biological effects.

GIPR belongs to the class B family of G-protein-coupled receptors. GIPR signaling has been identified in tissues involved in glucose and energy metabolism, including the pancreas, adipose tissue and brain.

The distinction between GIP and GIPR is fundamental:

Term Meaning
GIP The naturally occurring incretin hormone.
GIPR The receptor that responds to GIP.
GIPR agonist A molecule that activates the GIP receptor.
GIPR antagonist A molecule that blocks or inhibits GIP receptor signaling.
Dual agonist A drug that activates two receptor systems, such as GIPR and GLP-1R.
Triple agonist A drug that activates three receptor systems, such as GIPR, GLP-1R and the glucagon receptor.

GIP vs GLP-1: What's the Difference?

GIP and GLP-1 are both incretin hormones, but they are not identical. They are released from different intestinal cell populations and have different receptor distributions and biological effects.

Feature GIP GLP-1
Full name Glucose-dependent insulinotropic polypeptide Glucagon-like peptide-1
Main receptor GIPR GLP-1R
Hormone class Incretin Incretin
Insulin secretion Stimulates glucose-dependent insulin secretion Stimulates glucose-dependent insulin secretion
Glucagon Context dependent; effects depend on glucose conditions Generally suppresses glucagon during hyperglycemia
Gastric emptying Not the principal clinical mechanism Important pharmacological effect
Appetite Under active investigation; pharmacological GIPR signaling may influence appetite circuits Well established target of GLP-1-based medicines
Modern obesity medicines Usually used in combination with another receptor target Foundation of several approved obesity medicines

The most important modern lesson is that GIP and GLP-1 may be complementary rather than interchangeable. Tirzepatide was developed specifically to activate both GIPR and GLP-1R.

The precise contribution of GIPR versus GLP-1R activation to tirzepatide's clinical effects remains an active research question rather than a completely resolved mechanism. [PubMed: Clinical Potential of GIP in Type 2 Diabetes and Obesity]

GIP and Tirzepatide

Tirzepatide is the landmark example of GIP-based pharmacology in clinical medicine. It is a long-acting dual agonist of the GIP receptor and GLP-1 receptor.

The U.S. prescribing information describes tirzepatide as a GIPR and GLP-1R agonist. Its pharmacological effects include glucose-dependent insulin secretion, reduced glucagon secretion and reduced calorie intake, with appetite effects contributing to weight loss. [FDA prescribing information]

Tirzepatide was first approved in the United States for type 2 diabetes and later approved as Zepbound for chronic weight management. In December 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity. [FDA: Zepbound and obstructive sleep apnea]

Why does tirzepatide matter for GIP research?

Before tirzepatide, GIP had been overshadowed by GLP-1 in therapeutic development. Tirzepatide demonstrated that adding pharmacological GIPR activation to GLP-1R activation can produce substantial improvements in blood glucose and body weight.

This did not prove that GIP alone is a superior obesity therapy. Instead, it provided strong clinical evidence that GIPR signaling can contribute to a successful multi-receptor pharmacological strategy.

GIP and Weight Loss

One of the most common questions is: Does GIP cause weight loss or weight gain?

The scientific answer is more complicated than either statement.

Historically, some experimental findings led to the concept that GIP could promote nutrient storage and contribute to obesity. However, subsequent research has shown that manipulating GIPR can produce weight reduction under some conditions. The modern literature therefore treats the relationship between GIP signaling and obesity as considerably more complex than the older "GIP equals fat storage" model.

In humans, the strongest clinical weight-loss evidence comes from multi-receptor medicines, particularly tirzepatide, rather than from GIP administration alone.

Reviews published in 2025 and 2026 highlight the unresolved question of why both GIPR activation and inhibition can enhance GLP-1-based weight loss. [PubMed: GIPR antagonists in obesity] [PubMed: GIPR agonism and antagonism]

The GIPR Agonist vs Antagonist Paradox

One of the most important questions in GIP research: How can activating GIPR and blocking GIPR both potentially improve weight loss?

At first glance, the idea appears contradictory. If activating GIPR can contribute to weight loss, why would blocking GIPR also work?

Current research suggests that the two strategies may act through different biological mechanisms.

GIPR agonism

GIPR agonism may contribute to weight loss through effects on central metabolic signaling, nutrient handling and potentially thermogenesis, while also modifying some of the tolerability characteristics of GLP-1 receptor activation.

GIPR antagonism

GIPR antagonism may alter the balance of incretin signaling, potentially enhancing GLP-1-related effects and changing nutrient storage pathways. However, the complete mechanism remains unresolved.

A 2026 review explicitly describes this as a pharmacological paradox: both GIPR agonism and antagonism have been associated with enhanced efficacy when combined with GLP-1-based approaches. The authors emphasize that these strategies may converge on a similar therapeutic outcome through distinct mechanisms. [2026 review: GIPR agonism and antagonism]

Importantly, this is an active scientific question, not a settled explanation. Mechanistic hypotheses should not be presented as established clinical facts.

MariTide and GIPR Antagonism

Maridebart cafraglutide (MariTide) is one of the most visible examples of the alternative strategy: instead of activating GIPR, it combines GLP-1 receptor agonism with GIP receptor antagonism.

In a 2025 phase 2 randomized trial involving 592 participants, MariTide produced substantial weight reduction at 52 weeks. In the obesity cohort, mean body-weight changes across the active-treatment groups ranged from approximately 12.3% to 16.2% reduction, compared with approximately 2.5% with placebo. Gastrointestinal adverse events were common. [NEJM: MariTide Phase 2]

These findings are important because they demonstrate that GIPR antagonism is not merely a theoretical laboratory concept. At the same time, MariTide remained an investigational therapy, and phase 2 findings should not be interpreted as equivalent to the established regulatory status of approved medicines.

Why MariTide matters to the GIP field

MariTide creates an important scientific comparison:

Therapy concept GIPR action Other target Development status
Tirzepatide Agonist GLP-1R agonist Approved medicine
MariTide Antagonist GLP-1R agonist Investigational
Retatrutide Agonist GLP-1R + glucagon receptor agonism Investigational

Retatrutide: GIP + GLP-1 + Glucagon

Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates the GIP receptor, GLP-1 receptor and glucagon receptor.

It represents the next step in the evolution of incretin pharmacology: rather than manipulating one pathway, or two pathways, a single engineered molecule is designed to coordinate three metabolic signaling systems.

Important 2026 update

On September 29, 2026, the New England Journal of Medicine published Phase 3 TRIUMPH-1 results for retatrutide in adults with obesity without diabetes.

At 80 weeks, mean body-weight change was approximately −17.6% with 4 mg, −23.7% with 9 mg, and −25.0% with 12 mg, compared with −3.9% with placebo. The study was randomized and double-blind. [NEJM: Retatrutide Phase 3]

These results are important for understanding the potential of GIP-containing multi-receptor therapies, but they do not make retatrutide an approved medicine.

As of October 1, 2026, Lilly describes retatrutide as investigational, not approved by the FDA or another regulatory agency, and not available for public use outside clinical trials. [Lilly: Retatrutide status]

Do not confuse research status with commercial availability. Retatrutide products promoted or sold outside legitimate clinical research should not be treated as equivalent to an approved pharmaceutical product. Purity, identity, sterility, concentration and manufacturing quality may be uncertain.

What Does the Third Receptor Add?

Retatrutide adds glucagon receptor agonism to GIPR and GLP-1R activation. Glucagon can promote energy mobilization and influence hepatic glucose metabolism, but excessive glucagon activity can also raise blood glucose. The therapeutic challenge is therefore one of balancing several signals within one molecule.

This is why multi-receptor drugs are better understood as engineered pharmacological systems rather than simply "stronger GLP-1s."

Current research is examining whether combining GIP, GLP-1 and glucagon can increase weight reduction while maintaining an acceptable therapeutic window.

GIP-Based Therapies: A New Pharmacological Architecture

The evolution can be visualized as a progression:

Generation Target architecture Example Scientific concept
Single receptor GLP-1R Semaglutide Activate one incretin pathway
Dual receptor GIPR + GLP-1R Tirzepatide Coordinate two incretin pathways
Triple receptor GIPR + GLP-1R + glucagon receptor Retatrutide Coordinate incretin and glucagon signaling
Alternative dual pathway GIPR antagonism + GLP-1R agonism MariTide Test whether GIP blockade can complement GLP-1 activation

This is one reason GIP has become strategically important in obesity pharmacology: the GIP receptor is no longer being evaluated only as a standalone target. Researchers are asking how it can be combined, modulated or deliberately opposed within multi-pathway therapies.

What Does the Clinical Evidence Actually Show?

GIP research contains several different levels of evidence, and they should not be mixed together.

Question Current evidence Interpretation
Does GIP function as an incretin? Strong Established human physiology.
Does GIPR influence metabolism? Strong Supported by human physiology and pharmacology.
Does GIPR agonism contribute to tirzepatide's effects? Strong but mechanistically incomplete Tirzepatide clearly activates GIPR and GLP-1R; the precise relative contribution of each pathway remains under study.
Can GIPR agonism support weight loss? Strong for selected combination therapies Clinical evidence is strongest for dual and multi-receptor agents rather than GIP alone.
Can GIPR antagonism support weight loss? Promising Supported by preclinical work and phase 2 investigation of agents such as MariTide, but long-term clinical evidence remains limited.
Why do agonism and antagonism both work? Unresolved Multiple mechanisms have been proposed, but no single explanation has been established.
Is GIP alone an established weight-loss therapy? No The strongest current human evidence concerns pharmacological combinations involving GIPR.
Is retatrutide an approved medicine? No, as of Oct. 1, 2026 It remains investigational despite published phase 3 data.

GIP and Type 2 Diabetes

GIP has an important role in post-meal glucose regulation because it stimulates glucose-dependent insulin secretion.

However, GIP physiology in type 2 diabetes is not simply a question of whether more GIP is always better. Researchers have studied impaired incretin responses, receptor signaling, receptor desensitization and the effects of pharmacological combinations.

Tirzepatide provides clinical evidence that a therapy engaging both GIPR and GLP-1R can produce substantial improvements in glycemic control and body weight in people with type 2 diabetes.

A 2025 review of GIP clinical potential notes that tirzepatide has renewed interest in GIPR agonism, while also emphasizing that the relative contributions of GIPR and GLP-1R to its clinical effects have not been definitively established. [PubMed]

GIP and Adipose Tissue

GIP receptors are expressed in adipose tissue, making fat biology an important component of GIP research.

Earlier models emphasized the possibility that GIP could encourage nutrient storage in adipose tissue. More recent work suggests the physiology is more nuanced. Healthy adipose tissue can safely store excess lipid, whereas impaired adipose storage can contribute to ectopic lipid accumulation in organs such as the liver and muscle.

This distinction is important when interpreting GIPR-antagonist research. Blocking GIPR is not simply equivalent to "turning off fat storage," and the consequences of altering lipid trafficking may depend on the metabolic context.

GIP, Appetite and the Brain

GIPR is also expressed in regions of the central nervous system involved in metabolic regulation.

Researchers are investigating whether GIPR activation influences appetite, satiety, food reward and interactions with GLP-1-responsive neural circuits.

Some of the proposed mechanisms are based heavily on animal and experimental studies, so findings from those models should not automatically be presented as proven human mechanisms.

GIP and Lean Mass

Weight loss is not synonymous with fat loss. Any serious metabolic-medicine discussion should distinguish changes in fat mass, lean mass, muscle mass and total body weight.

Tirzepatide pharmacology results in greater loss of fat mass than lean mass, but lean tissue can still decline during substantial weight reduction. The clinical question is therefore not simply whether a medicine reduces body weight, but how body composition changes over time.

This makes resistance training, adequate protein intake and overall nutritional adequacy important topics for future GIP and incretin research, while avoiding the assumption that any particular supplement or intervention is proven to prevent all treatment-associated lean-mass loss.

GIP, Metabolic Health and Longevity

GIP is increasingly being discussed in the context of broader metabolic health, including glucose control, adipose-tissue function, liver metabolism and cardiovascular risk factors.

However, an important distinction should be maintained between:

1. Improving a metabolic risk factor
and

2. Proving that a therapy extends human lifespan.

Weight loss, improved glycemic control or changes in cardiometabolic biomarkers can be clinically meaningful without proving an effect on overall longevity.

For OneDayMD's longevity content, GIP-based medicines should therefore be discussed as metabolic-health interventions with potentially broader consequences, rather than as established anti-aging drugs.

Safety, Limitations and Unknowns

The safety profile of a GIP-containing therapy depends on the specific molecule. It is not scientifically accurate to treat "GIP peptides" as one homogeneous class.

Established versus investigational therapies

Tirzepatide is an approved pharmaceutical with regulatory labeling, while retatrutide and other emerging multi-receptor therapies remain investigational as of October 2026.

Investigational clinical-trial results provide useful evidence, but they do not substitute for regulatory review, approved prescribing information, post-marketing surveillance and long-term real-world safety data.

Gastrointestinal effects

Gastrointestinal adverse effects are an important issue with incretin-based therapies. In the MariTide phase 2 study, gastrointestinal adverse events were common. Dose escalation and starting-dose strategies affected tolerability in that trial. [NEJM: MariTide]

Long-term evidence

The long-term effects of manipulating GIPR remain an active research area. This is particularly important for newer therapies that produce profound and sustained changes in body weight and metabolism.

Animal-to-human translation

GIP research illustrates an important lesson in translational medicine: mechanisms observed in mice or other experimental systems do not always predict human outcomes.

Species differences in GIP signaling, receptor biology and energy metabolism are specifically discussed in the literature on GIPR agonism and antagonism. [PubMed: GIPR antagonist pharmacology]

What About "GIP Peptides" Sold Online?

Internet marketing sometimes uses terms such as "GIP peptide," "GIP therapy" or "research peptide" as if they referred to established treatments.

This terminology can be misleading.

A peptide sold online is not automatically equivalent to an FDA-approved or other regulator-approved pharmaceutical. The identity, purity, concentration, sterility, manufacturing controls and clinical evidence may differ substantially.

Retatrutide deserves particular caution. As of October 2026, Lilly describes it as investigational and states that it is not approved for public use. [Lilly: retatrutide safety and availability]

Important: Do not treat an online "research peptide" product as interchangeable with a clinical-trial drug or an approved pharmaceutical. Medical decisions involving peptide therapies should be made with a qualified healthcare professional.

GIP Evidence Map

To keep the GIP Academy transparent, OneDayMD can classify evidence using an editorial E0–E5 framework. The goal is to distinguish hypothesis-generating research from established clinical evidence.

Level Evidence category Typical examples How to interpret
E0 Hypothesis / early concept Theoretical mechanisms Useful for research direction, not proof.
E1 Preclinical / laboratory Cell and animal studies Mechanistic evidence requiring human validation.
E2 Human observational / physiological Human hormone studies, genetics, associations Useful for biological plausibility but not necessarily causal.
E3 Early clinical Phase 1–2 trials Important clinical signal but generally insufficient for definitive conclusions.
E4 Randomized clinical evidence Phase 3 randomized trials Stronger evidence of efficacy and safety in the studied population.
E5 Established clinical/regulatory evidence Approved therapies supported by substantial clinical evidence Highest level in this editorial framework; still requires ongoing safety surveillance.

GIP Therapy Evidence Snapshot: 2026

Therapy GIP action Clinical evidence Status as of Oct. 1, 2026 Approx. evidence level
Tirzepatide GIPR agonist + GLP-1R agonist Large randomized trials and regulatory review Approved medicine E5
MariTide GIPR antagonist + GLP-1R agonist Phase 2 randomized trial Investigational E3
Retatrutide GIPR + GLP-1R + glucagon receptor agonist Published Phase 3 randomized data Investigational E4
GIP alone for weight loss GIPR signaling Human evidence remains limited/inconclusive relative to approved multi-receptor therapies Not an established obesity treatment E1–E2

The Future of GIP-Based Therapies

GIP research is moving beyond the question of whether GIP is "good" or "bad."

The more useful scientific questions are:

Which receptor? GIPR, GLP-1R, glucagon receptor or another metabolic target?

Which direction? Agonism, antagonism or context-dependent modulation?

Which combination? Dual agonists, triple agonists, antibody-peptide conjugates or other engineered molecules?

Which patient? Obesity, type 2 diabetes, fatty liver disease, sleep apnea or another metabolic condition?

Which outcome? Body weight, fat mass, glucose control, cardiovascular events, organ health, functional status or long-term health?

This suggests that the future of peptide medicine may be less about finding one "best peptide" and more about designing precisely engineered multi-receptor pharmacology.

Potential research directions

Research area Key question
GIPR agonism How does GIPR activation contribute to the efficacy and tolerability of GLP-1-based therapy?
GIPR antagonism Can selective GIPR blockade consistently improve outcomes when combined with GLP-1R activation?
Triple agonists Can GIP + GLP-1 + glucagon provide greater metabolic benefits while maintaining tolerability?
Body composition How can substantial fat loss be achieved while preserving lean tissue and physical function?
Metabolic disease Can GIP-targeting therapies improve conditions beyond obesity and glucose control?
Precision medicine Will biomarkers identify which patients benefit most from specific receptor combinations?

GIP Academy: The OneDayMD Knowledge Graph

The GIP topic is best understood as a connected knowledge graph rather than a series of isolated articles.

Entity Relationship Evidence Clinical question
GIP Signals through GIPR Human physiology What does GIP normally do?
GIPR Interacts with metabolic pathways Physiology + experimental research Where does GIPR act?
GIPR Combines with GLP-1R targeting Randomized clinical evidence Why does dual agonism work?
Tirzepatide GIPR + GLP-1R agonism Large RCTs + regulatory evidence How is an approved dual agonist used?
MariTide GIPR antagonism + GLP-1R agonism Phase 2 evidence Can blocking GIPR also work?
Retatrutide GIPR + GLP-1R + glucagon receptor agonism Phase 3 evidence Can triple agonism improve outcomes further?

What GIP Research Does Not Yet Prove

A responsible GIP evidence guide should be as explicit about uncertainty as it is about promising findings.

Current research does not establish that:

  • GIP alone is a proven weight-loss drug.
  • Every GIP-containing peptide will produce the same results as tirzepatide.
  • Animal findings automatically translate into equivalent human effects.
  • Retatrutide is currently an approved treatment.
  • Changes in body weight automatically demonstrate increased longevity.
  • One GIPR strategy is universally superior to another.

The evidence is instead pointing toward a more sophisticated model in which receptor combinations, dose, duration, pharmacokinetics, tissue targeting and patient biology all matter.

Frequently Asked Questions About GIP

What does GIP stand for?

GIP stands for glucose-dependent insulinotropic polypeptide. It is an incretin hormone secreted mainly by K cells in the upper small intestine after food intake.

Is GIP the same as GLP-1?

No. GIP and GLP-1 are different incretin hormones with different receptors and overlapping but distinct physiological effects.

What is GIPR?

GIPR is the glucose-dependent insulinotropic polypeptide receptor. It is the principal receptor through which GIP signaling occurs.

Why is GIP important in tirzepatide?

Tirzepatide activates both GIPR and GLP-1R. This dual-receptor design is a major reason GIP has become an important target in modern metabolic pharmacology.

Does GIP cause weight gain?

GIP biology cannot be reduced to a simple weight-gain or weight-loss effect. Earlier experimental models raised concerns about GIP-related nutrient storage, while newer pharmacological research shows that both GIPR activation and inhibition can contribute to weight reduction in specific contexts.

Can blocking GIPR cause weight loss?

Investigational evidence suggests that GIPR antagonism can contribute to weight loss, especially when combined with GLP-1 receptor activation. MariTide is an important clinical example, but long-term evidence is still developing.

What is retatrutide?

Retatrutide is an investigational triple agonist targeting GIPR, GLP-1R and the glucagon receptor. Phase 3 obesity results were published in the New England Journal of Medicine in September 2026, but retatrutide remained unapproved as of October 1, 2026.

Is retatrutide approved?

No. As of October 1, 2026, retatrutide remains investigational and is not approved by the FDA or another regulatory agency.

What is MariTide?

Maridebart cafraglutide, known as MariTide, is an investigational peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism. It produced substantial weight reduction in a phase 2 obesity trial.

Are GIP peptides the same as approved medications?

No. The term "GIP peptide" can refer to very different molecules. An online research peptide should not be assumed to be equivalent to an approved pharmaceutical or a clinical-trial product.

Bottom Line

GIP has evolved from an overlooked incretin hormone into a major target of modern metabolic drug development.

The clinical success of tirzepatide established that GIPR activation can be successfully combined with GLP-1R activation. Retatrutide is now extending the concept into triple GIP/GLP-1/glucagon receptor agonism, while MariTide is testing the seemingly opposite strategy of GIPR antagonism plus GLP-1R agonism.

The most important lesson is that GIP is not simply "the second GLP-1." It is a complex metabolic signaling system whose therapeutic potential may depend on whether the receptor is activated, blocked or combined with other pathways.

As evidence accumulates, the key questions will move from "Does GIP work?" toward more precise questions about which GIP strategy, for which patient, in which receptor combination, at which dose, for which clinical outcome.

OneDayMD evidence principle: promising mechanisms are not the same as proven clinical outcomes. We distinguish biological plausibility, preclinical evidence, early clinical trials, randomized trials and regulatory status so readers can see not only what is known, but also what remains uncertain.

Sources & Further Reading

  1. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine, published September 29, 2026. DOI / NEJM
  2. Clinical Potential of GIP in Type 2 Diabetes and Obesity. Diabetes, 2026. PubMed
  3. Glucose-dependent insulinotropic polypeptide (GIP). Review of GIP biology and therapeutic implications, 2025. PubMed
  4. Physiology and clinical applications of GIP. Review of GIP secretion, receptors and therapeutic development. PubMed
  5. One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy. Appetite, 2026. PubMed
  6. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale. Diabetes, 2025. PubMed
  7. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. New England Journal of Medicine, 2025. NEJM
  8. Tirzepatide prescribing information. U.S. Food and Drug Administration. FDA label
  9. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration, December 20, 2024. FDA
  10. What to know about retatrutide. Eli Lilly, updated September 2026. Lilly

Related OneDayMD Resources

  • Peptide Academy: Complete Evidence-Based Guide
  • GIP vs GLP-1: Differences in Biology, Mechanism and Clinical Use
  • Tirzepatide: Complete Evidence Guide
  • Retatrutide: Complete 2026 Evidence Guide
  • GIP Clinical Trials: Evidence Tracker
  • MariTide and GIPR Antagonism: Evidence Guide

Medical disclaimer: This page is for educational purposes and does not provide individualized medical advice, diagnosis or treatment recommendations. Prescription medicines and investigational therapies should be discussed with a qualified healthcare professional. Regulatory status can change, so readers should consult the relevant regulator and current prescribing information.

Comments

Post a Comment

Popular posts from this blog

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Updated September 2026 GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The most defensible strategy is therefore not to avoid effective obesity treatment, but to improve the quality of weight loss with adequate protein, progressive resistance training, sufficient nutrition a...
Read more

Start GLP-1 Weight Loss in 2026: Compare Wegovy, Zepbound, Foundayo & Oral Options

Image
2026 Evidence & Treatment Guide GLP-1 treatment has moved beyond the original Ozempic vs. Wegovy conversation. In 2026, people considering medical treatment for obesity may encounter weekly semaglutide, higher-dose Wegovy HD, oral Wegovy, weekly tirzepatide, and the new oral GLP-1 medicine Foundayo (orforglipron) by Eli Lilly . The important question is no longer simply "Which GLP-1 is strongest?" A better approach is to compare the medicines by indication, clinical evidence, route, tolerability, cardiovascular or sleep-apnea considerations, cost, access, long-term maintenance, and the person's broader health goals. Updated: September 27, 2026   |   Regulatory reference: U.S. FDA labeling   |   Scope: Adult obesity treatment unless otherwise stated Important medical note: This page is educational information, not a diagnosis or personal treatm...
Read more

Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss: What the Evidence Shows

Image
Updated September 25, 2026 Popular GLP-1-based medicines are now at the center of a growing legal and medical debate over a rare form of sudden vision loss called nonarteritic anterior ischemic optic neuropathy (NAION) . Patients in the United States have filed lawsuits against the manufacturers of widely used medicines including Ozempic, Wegovy, Mounjaro and Zepbound , alleging that the drugs caused NAION and that patients were not adequately warned about the potential risk. Those lawsuits are allegations at the moment—not findings that the medications caused the injuries. The scientific evidence is still evolving and is not completely consistent. Importantly, the regulatory evidence is stronger for semaglutide , the active ingredient in Ozempic, Wegovy and Rybelsus, than for the entire GLP-1 drug class. Patient safety message: Sudden or rapidly worsening vision loss is not a symptom to monitor at home. Anyone experiencing sudden vision loss while taking a GLP-1-based medi...
Read more

SELECT, STEP, SURPASS, SURMOUNT & FLOW: What the Landmark Semaglutide and Tirzepatide Trials Actually Prove (2026)

Image
By Dr. Frank Yap, MD  |  Medically reviewed by One Day MD Review Team  |  Last updated: September 2026 Quick Answer SELECT showed that semaglutide 2.4 mg cuts major cardiovascular events by 20% in people with overweight/obesity and existing heart disease who do not have diabetes. The STEP program (STEP 1–5, STEP 8, and the newer STEP UP trials) established semaglutide's weight-loss profile, with losses ranging from roughly 10% to over 20% of body weight depending on dose, population, and duration. The SURPASS program showed that tirzepatide — a dual GIP/GLP-1 agonist — produces larger HbA1c and weight reductions than semaglutide in type 2 diabetes, and the newly published SURPASS-CVOT (December 2025) confirmed tirzepatide is at least as cardioprotective as dulaglutide. FLOW showed semaglutide cuts major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease, which led the FDA to approve a dedicated kidney-protection in...
Read more

Top Peptide Protocols 2026: Best Stacks for Fat Loss, Recovery, Anti-Aging & Longevity

Image
By Dr. Frank Yap, MD  |  Originally published April 2026  |  Fully updated August 26, 2026 for the FDA's July 2026 compounding committee vote Quick Answer As of August 2026, GLP-1 receptor agonists (semaglutide, tirzepatide) remain the only peptides in this guide with full FDA approval. On July 23–24, 2026, an FDA advisory committee (PCAC) recommended adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the list of substances compounding pharmacies may use — but that vote is non-binding, and none of the six is lawful to compound yet; formal rulemaking is expected to take 12–24 months. Separately, AOD-9604 failed its pivotal human obesity trial back in 2007. The best human evidence among the non-GLP-1 peptides here belongs to topical GHK-Cu (skin) and Selank (anxiety); the weakest belongs to BPC-157 and TB-500 (mostly animal data). Any protocol should run through a licensed physician — not a gray-market vendor. Medical & regu...
Read more

9 Best Berberine Supplements (2026 Review): Evidence, Dosage & New EU Safety Data

Image
By Dr Frank Yap, MD | Medically reviewed by the One Day MD Editorial Team | Last updated: August 2026 | Original publication: March 2023 Quick Answer A 2024–2025 meta-analysis of 50 RCTs (4,150 patients) confirms berberine modestly but reliably lowers fasting glucose, HbA1c, LDL cholesterol and inflammatory markers in type 2 diabetes and metabolic syndrome — solid, Tier 1a evidence. It is not "nature's Ozempic." Semaglutide produces roughly 10–15%+ body-weight loss in trials; berberine averages only about 2–4 lb a month. The mechanisms and effect sizes aren't comparable. Typical dosing is 500 mg, 2–3x daily with meals (1,000–1,500 mg/day). Bioavailability — not the milligram number on the label — is the biggest real difference between brands. New in 2026: A draft EU/UK scientific opinion (EFSA/COT, March 2026) flagged in-vitro genotoxicity signals, confirmed the CYP3A4 drug-interaction risk, and stated that regulators cannot yet establish a formal "...
Read more

Bryan Johnson's Supplements List: Insider's Guide (2026 Update)

Image
By Editorial Team , medically reviewed by Dr Frank Yap, MD | Last updated: August 2026 | Originally published: June 2024 Related: Bryan Johnson's Blueprint Longevity Mix Review Quick Answer Bryan Johnson's protocol has been substantially simplified since the 40+ item pill list he published in 2024. His January 2026 update replaces most of the granular, individually-dosed compounds (NAC, red yeast rice, DHEA, genistein, standalone taurine, and others) with combined formulations — Essential Capsules, Advanced Antioxidants, and a merged Ashwagandha & Rhodiola product — alongside NR or NMN, omega-3, and Proferrin. His daily creatine dose has increased to 7.5 g total. The bigger change is on the prescription side: he has added three cardiometabolic drugs not previously disclosed — the SGLT2 inhibitor Jardiance (empagliflozin) , the PCSK9 inhibitor Repatha (evolocumab) , and the ARB candesartan — and switched metformin from continuous daily dosing to a s...
Read more

Best Injectable Peptides for Anti Aging 2026

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: August 2026 Quick Answer Most content ranking for "injectable peptides for anti-aging" actually describes topical cosmetic peptides (Matrixyl, Argireline, copper peptide serums) that are never injected at all. True injectable anti-aging peptides fall into distinct categories: skin-quality "boosters" used in medical aesthetics (injectable GHK-Cu, growth-factor mesotherapy), growth-hormone secretagogues (sermorelin, tesamorelin, CJC-1295, ipamorelin), regenerative peptides (BPC-157, TB-500), and cellular/metabolic peptides (MOTS-c, epitalon). Evidence quality varies enormously — from large randomized trials (tesamorelin, GLP-1 drugs) down to animal-only data (BPC-157, most "longevity" peptides). As of August 2026, several popular peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, epitalon) were recommended by an FDA advisory panel for legal compounding but are not yet...
Read more

NAC vs NAD vs NR vs NMN vs Niacin: What Are the Differences?

Image
By the One Day MD Editorial Team  |  Originally published September 2020  |  Last updated and medically fact-checked: August 2026 NAD, NAD+, NADH, NR, NMN, niacin, niacinamide, and NAC — these overlapping names cause constant confusion, and understandably so. Some are simply different names for the same molecule. Others are metabolic precursors that your body converts, step by step, into NAD+. One of them, NAC, isn't related to NAD+ metabolism at all. This guide breaks down what each compound actually does, how the human evidence stacks up as of 2026, and where the real safety trade-offs lie — including the January 2026 head-to-head human trial that finally pitted NR against NMN directly, and the FDA's 2025 reversal on NMN's legal status. Quick Answer NAD+ is the coenzyme your cells actually need for energy production and DNA repair, and it can't be taken as an oral supplement because it's too large a molecule to survive digestion intact. NR, NMN, n...
Read more

Healthy Lifestyle and Longevity (2026): The Evidence on Diet, Exercise, Supplements & Anti-Aging Drugs

Image
By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Originally published: August 24, 2026 | Last updated: September 29, 2026 Quick Answer: A healthy lifestyle may add years to life, and potentially a decade or more in some populations, but no scientifically valid number applies to everyone. The biggest gains come from not smoking, regular physical activity, a high-quality diet, a healthy body weight, and controlled cardiovascular and metabolic risk factors . One influential U.S. analysis projected about 14 more years for women and 12 for men at age 50 for people with five low-risk habits versus none, but that is an observational estimate, not a guarantee. Supplements and anti-aging drugs are not proven to add a specific number of years. Preventing falls and injury also protects healthspan: balance and strength training is the best-supported strategy. In this guide What the Best Evidence Shows Other Studies Point the Same Way How Much Does Each Lifestyle...
Read more